DrugDashboards

Ella

ulipristal acetate · ULIPRISTAL ACETATE 30 mg/1 · Tablet · Oral · PMI Branded Pharmaceuticals, Inc.

NDC 73302-0456-01 · 1 BLISTER PACK in 1 CARTON / 1 TABLET in 1 BLISTER PACK · NDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $37.10 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$20.00$40.00Sep 2020Sep 2026$37.10
37 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$1113.01
#90 count
$3339.02

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$4.9M
92,847 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 2 active manufacturers+20

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for ulipristal acetate (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
NDA022474
TE code
AB
Approval date
Aug 13, 2010
Patents / exclusivity
8 patents, 0 exclusivities
TypeNumber / codeExpires
patent8426392Jun 12, 2030
patent8962603Jun 12, 2030
patent8512745Jun 2, 2030
patent10159681Apr 13, 2030
patent10772897Apr 13, 2030
patent9283233Apr 13, 2030
patent8735380Feb 20, 2029
patent9844510Dec 8, 2028

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of ulipristal acetate (Tablet)

LabelerStrengthFirst seenLast seen
A-S Medication SolutionsULIPRISTAL ACETATE 30 mg/1Jul 15, 2026Sep 2, 2026
PMI Branded Pharmaceuticals, Inc.ULIPRISTAL ACETATE 30 mg/1Jul 24, 2026Aug 28, 2026
Hra Pharma America, Inc.ULIPRISTAL ACETATE 30 mg/1Jul 15, 2026Jul 22, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ella — NDC 73302-0456-01," retrieved September 3, 2026, https://drugdashboards.com/drug/73302045601.

Free to cite with attribution — see how the data is put together.